- Home
- MIRA vs SBFM Comparison
MIRA vs SBFM Comparison
Compare MIRA & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- SBFM
- Stock Information
- Founded
- MIRA 2020
- SBFM 2006
- Country
- MIRA United States
- SBFM United States
- Employees
- MIRA N/A
- SBFM N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- MIRA Health Care
- SBFM Health Care
- Exchange
- MIRA Nasdaq
- SBFM Nasdaq
- Market Cap
- MIRA 17.1M
- SBFM 3.7M
- IPO Year
- MIRA 2023
- SBFM N/A
- Fundamental
- Price
- MIRA $1.05
- SBFM $3.14
- Analyst Decision
- MIRA Strong Buy
- SBFM
- Analyst Count
- MIRA 2
- SBFM 0
- Target Price
- MIRA $14.00
- SBFM N/A
- AVG Volume (30 Days)
- MIRA 552.1K
- SBFM 90.8K
- Earning Date
- MIRA 11-11-2024
- SBFM 11-11-2024
- Dividend Yield
- MIRA N/A
- SBFM N/A
- EPS Growth
- MIRA N/A
- SBFM N/A
- EPS
- MIRA N/A
- SBFM N/A
- Revenue
- MIRA N/A
- SBFM $30,481,982.00
- Revenue This Year
- MIRA N/A
- SBFM $86.70
- Revenue Next Year
- MIRA N/A
- SBFM $126.76
- P/E Ratio
- MIRA N/A
- SBFM N/A
- Revenue Growth
- MIRA N/A
- SBFM 109.82
- 52 Week Low
- MIRA $0.51
- SBFM $2.42
- 52 Week High
- MIRA $6.40
- SBFM $660.00
- Technical
- Relative Strength Index (RSI)
- MIRA 38.97
- SBFM 52.62
- Support Level
- MIRA $1.04
- SBFM $2.85
- Resistance Level
- MIRA $1.20
- SBFM $3.05
- Average True Range (ATR)
- MIRA 0.07
- SBFM 0.14
- MACD
- MIRA 0.02
- SBFM 0.03
- Stochastic Oscillator
- MIRA 19.44
- SBFM 85.29
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.